Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer

Chen, Ming-Huang; Chang, Peter Mu Hsin; Chen, Po Min; Tzeng, Cheng Hwai; Chu, Pen–Yuan; Chang, Shun‐Hsyung; Yang, Muh Hwa

doi:10.1007/s00432-009-0625-1

Cited by 61 publications

(77 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[137][138][139][140] The clinical features, associated malignancies, diagnostic studies, and treatment of paraneoplastic hematologic syndromes are listed in Table 4. 137,138,[140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155][156] eoSInopHIlIa Paraneoplastic eosinophilia represents a subset of secondary eosinophilia that appears due to tumor production of the eosinophil growth factors interleukin (IL)-3, IL-5, and GM-CSF. 137,157 By contrast, primary eosinophilia, a separate diagnosis encountered in hematology-oncology practices, often represents a clonal phenomenon caused directly by a hematologic neoplastic process.…”

Section: Paraneoplastic Hematologic Syndromesmentioning

confidence: 99%

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

Pelosof

Gerber

2010

Mayo Clinic Proceedings

569

514

View full text Add to dashboard Cite

Section: Paraneoplastic Hematologic Syndromesmentioning

confidence: 99%

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

Pelosof

Gerber

2010

Mayo Clinic Proceedings

569

514

View full text Add to dashboard Cite

“…Hematologic abnormalities have been suggested as dismal prognosis signs of human cancers due to the implication of pathophysiologic responses to disseminated disease [1]. Pretreatment anemia is associated with shorter survival in numerous carcinoma patients, including lung carcinoma [2], cervical carcinoma [2,3], head and neck cancer [2,4], and esophageal cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Impact of pretreatment hematologic profile on survival of colorectal cancer patients

et al. 2010

View full text Add to dashboard Cite

Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors. The aim of our study was to determine the prevalence of abnormalities in the hematologic profile in patients with colorectal cancer before treatment and to evaluate if such a profile could be used for prognostic evaluations. We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as colorectal cancers between May 2005 and August 2009. All subjects were investigated regarding levels of white blood cells, platelets, and hemoglobin concentration. Survival was compared by using the log-rank test on the Kaplan-Meier life table. Multivariate Cox regression analysis was used to evaluate if the pretreatment hematologic profile was independent prognostic factor. We identified 363 patients with colorectal cancer and 315 patients with benign diseases for the final analysis. The percentages of leukocytosis, anemia, and thrombocytosis were significantly higher in colorectal cancer patients than in patients with benign diseases. Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival. The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival. The cumulative effect of anemia and thrombocytosis yielded shorter survival. Anemia and thrombocytosis can be considered as useful prognostic markers in patients with colorectal cancer.

show abstract

“…6 In addition, monocytosis has also been reported to indicate a worse prognosis in patients with adult T-cell leukemia/lymphoma 7 and head and neck cancers. 8 In patients with primary myelofibrosis, there is lack of information in relation to the development of monocytosis during the course of the disease. One study, however, has reported that the presence of absolute monocytosis at disease outset had a statistically significant, independent predictive value of inferior survival in younger patients with primary myelofibrosis.…”

mentioning

confidence: 99%

Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease

et al. 2013

View full text Add to dashboard Cite

Primary myelofibrosis is a type of chronic myeloproliferative neoplasm characterized by progressive bone marrow failure with worsening cytopenia and in a subset of patients, progression to acute leukemia. Published data in patients with myelodysplastic syndromes have shown that the development of monocytosis in the course of myelodysplastic syndromes is associated with a poor prognosis. A similar occurrence has been only sporadically reported in patients with primary myelofibrosis. Over a period of four years we identified 10 out of 237 cases of primary myelofibrosis who developed persistent absolute monocytosis (41 Â 10 9 /l) during the course of disease (5 men and 5 women; median age/range: 68 years/52-82). Monocytosis developed at a median interval of 42 months from diagnosis (range: 1-180) and persisted for a median period of 23 months (range: 2-57). Five patients died after developing monocytosis (range: 20-188 months) and two experienced worsening disease and became transfusion dependent. Monocytosis was associated with increased white blood cells, decreased hemoglobin, decreased platelet count, and the presence of circulating blasts. In three cases, bone marrow biopsies after the onset of monocytosis showed marked myelomonocytic proliferation with morphological shifting from a typical primary myelofibrosis marrow appearance to aspects compatible with an overt 'secondary' chronic myelomonocytic leukemia. Before the development of monocytosis, 5 of 10 patients carried the JAK2V617F mutation; five patients showed karyotypic alterations. No change in JAK2 mutational status or cytogenetic evolution were associated with the development of monocytosis. Four of nine patients analyzed showed KRAS mutation in codon 12 or 13 with low allele burden. This is the first study correlating monocytosis developing in primary myelofibrosis patients with bone marrow morphology, laboratory data, molecular analysis and clinical follow-up. Development of monocytosis in patients with established primary myelofibrosis is associated with rapid disease progression and these patients should be considered as a high-risk group associated with short survival.

show abstract

Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer

Abstract: A pretreatment hematologic profile can be considered as a useful prognostic marker in patients with head and neck cancer.

Cited by 61 publications

References 35 publications

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

Impact of pretreatment hematologic profile on survival of colorectal cancer patients

Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease

Contact Info

Product

Resources

About